<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03428217</url>
  </required_header>
  <id_info>
    <org_study_id>CX-839-008</org_study_id>
    <nct_id>NCT03428217</nct_id>
  </id_info>
  <brief_title>CANTATA: CB-839 With Cabozantinib vs. Placebo With Cabozantinib in Patients With Metastatic Renal Cell Carcinoma</brief_title>
  <acronym>CANTATA</acronym>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination With Cabozantinib (CB-Cabo) vs. Placebo With Cabozantinib (Pbo-Cabo) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC) - CANTATA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Calithera Biosciences, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Calithera Biosciences, Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a randomized Phase 2 evaluation of CB-839 in combination with cabozantinib
      versus placebo with cabozantinib in patients with advanced or metastatic Renal Cell
      Carcinoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a randomized Phase 2 evaluation of CB-839 in combination with cabozantinib
      versus placebo with cabozantinib in Renal Cell Carcinoma patients with at least one and not
      more than 2 prior therapies in the advanced or metastatic setting.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 27, 2018</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is a double blinded placebo-controlled study where patients will be randomized 1:1 to either CB-839 plus cabozantinib or placebo plus cabozantinib</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double-blind in place with blinded Independent Radiology Committee reviewing adjudicated progression free survival of patients</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>18 months</time_frame>
    <description>Assessed by Independent Radiology Committee (IRC)-adjudicated PFS per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) of study patients treated with CB-Cabo vs Pbo-Cabo</measure>
    <time_frame>36 months</time_frame>
    <description>Assessed by time from randomization to death by any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS of patients treated with CB-Cabo vs Pbo-Cabo</measure>
    <time_frame>18 months</time_frame>
    <description>Assessed by investigator per RECIST v1.1</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">298</enrollment>
  <condition>Advanced Renal Cell Carcinoma</condition>
  <condition>Metastatic Renal Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>CB-Cabo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CB-839 orally twice daily + cabozantinib orally once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pbo-Cabo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo orally twice daily + cabozantinib orally once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CB-839</intervention_name>
    <description>Oral glutaminase inhibitor</description>
    <arm_group_label>CB-Cabo</arm_group_label>
    <other_name>Glutaminase inhibitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cabozantinib</intervention_name>
    <description>Oral receptor tyrosine kinase inhibitor</description>
    <arm_group_label>CB-Cabo</arm_group_label>
    <arm_group_label>Pbo-Cabo</arm_group_label>
    <other_name>Cabometyx</other_name>
    <other_name>Cabometriq</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablets</description>
    <arm_group_label>Pbo-Cabo</arm_group_label>
    <other_name>Placebo Tablets</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Documented histological or cytological diagnosis of renal cell carcinoma with a
             clear-cell component

          -  Adult patients

          -  Karnofsky Performance Score (KPS) â‰¥ 70%

          -  Measurable Disease per RECIST 1.1

          -  1-2 lines of prior therapy for advanced or metastatic RCC including at least one
             antiangiogenic therapy or nivolumab + ipilimumab

          -  Adequate hepatic, renal, cardiac and hematologic function

        Exclusion Criteria:

          -  Prior treatment with cabozantinib (or other MET inhibitor) or CB-839

          -  Receipt of other anticancer therapy within 2 - 6 weeks, depending on the treatment

          -  Untreated or active brain metastases or central nervous system cancer, as defined per
             protocol

          -  Prior gastric surgery, small bowel resection, or other conditions that may impede
             adequate absorption of oral study drug

          -  Known active infection with HIV, Hepatitis B or C virus

          -  Requirement for continued proton pump inhibitor after randomization
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bridget O'Keeffe, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Calithera Biosciences, Inc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trials Administrator</last_name>
    <phone>650-870-1000</phone>
    <email>clinicaltrials@calithera.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Clinical Admin</last_name>
    <phone>650-870-1000</phone>
    <email>clinicaltrials@calithera.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Georgetown University Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nancy Dawson, MD</last_name>
      <phone>202-444-2198</phone>
      <email>Nad28@georgetown.edu</email>
    </contact>
    <investigator>
      <last_name>Nancy Dawson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Georgia Cancer Center at Augusta University</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jigarkumar Parikh, MD</last_name>
      <phone>706-721-1206</phone>
      <email>cancer_center_trials@augusta.edu</email>
    </contact>
    <investigator>
      <last_name>Jigarkumar Parikh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwest Georgia Oncology Centers, PC</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steve McCune, MD</last_name>
      <phone>770-281-5010</phone>
    </contact>
    <investigator>
      <last_name>Steve McCune, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Goshen Center for Cancer Care</name>
      <address>
        <city>Goshen</city>
        <state>Indiana</state>
        <zip>46526</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jen Hughey</last_name>
      <phone>574-364-2974</phone>
      <email>jhughey@goshenhealth.com</email>
    </contact>
    <investigator>
      <last_name>Sachin Agarwal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>East Jefferson General Hospital</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicole Guttierrez</last_name>
      <phone>504-503-5368</phone>
      <email>nguttirrez@ejgh.org</email>
    </contact>
    <investigator>
      <last_name>Thomas Cosgriff, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hattiesburg Clinic Hematology/Oncology</name>
      <address>
        <city>Hattiesburg</city>
        <state>Mississippi</state>
        <zip>39401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tammy McBeth</last_name>
      <phone>601-261-1700</phone>
      <email>tmcbeth@forrestgeneral.com</email>
    </contact>
    <investigator>
      <last_name>John Hrom, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>San Juan Oncology Associates, PC</name>
      <address>
        <city>Farmington</city>
        <state>New Mexico</state>
        <zip>87401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosemarie Mestas</last_name>
      <phone>505-564-6874</phone>
      <email>rosemarie@sjonc.com</email>
    </contact>
    <investigator>
      <last_name>Sardar Imam, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>North Shore Hematology Oncology Associates PC dba NY Cancer and Blood Specialists</name>
      <address>
        <city>East Setauket</city>
        <state>New York</state>
        <zip>11733</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Chu, MD</last_name>
      <phone>631-675-5075</phone>
      <email>researchpi@nycancer.com</email>
    </contact>
    <investigator>
      <last_name>David Chu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NYU Winthrop Hospital</name>
      <address>
        <city>Mineola</city>
        <state>New York</state>
        <zip>11501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Brown</last_name>
      <phone>516-663-3115</phone>
      <email>JLBrown@nyuwinthrop.org</email>
    </contact>
    <investigator>
      <last_name>Mary O'Keeffe, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northern Westchester Hospital</name>
      <address>
        <city>Mount Kisco</city>
        <state>New York</state>
        <zip>10549</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan Goldberg, MD</last_name>
      <phone>914-241-1050</phone>
      <email>jgoldberg@cmmedical.com</email>
    </contact>
    <investigator>
      <last_name>Jonathan Goldberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stony Brook Cancer Center</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Audrey Anderson</last_name>
      <phone>631-638-0829</phone>
      <email>audrey.anderson@stonybrookmedicine.edu</email>
    </contact>
    <investigator>
      <last_name>Yue Zhang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Francis Hospital Cancer Center</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda Lowery</last_name>
      <phone>864-603-6214</phone>
      <email>Amanda_Lowery@bshsi.org</email>
    </contact>
    <investigator>
      <last_name>Robert Siegel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West Cancer Center</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda Fletcher</last_name>
      <phone>901-683-0055</phone>
      <email>afletcher@westclinic.com</email>
    </contact>
    <investigator>
      <last_name>Daniel Vaena, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nizar Tannir, MD</last_name>
      <phone>713-563-1895</phone>
      <email>ntannir@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Nizar Tannir, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Utah, Huntsman Cancer Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jill Broghammer</last_name>
      <phone>801-213-6232</phone>
      <email>jill.broghammer@hci.utah.edu</email>
    </contact>
    <investigator>
      <last_name>Neeraj Agarwal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kadlec Clinic Hematology and Oncology</name>
      <address>
        <city>Kennewick</city>
        <state>Washington</state>
        <zip>99336</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather Johansen</last_name>
      <phone>509-783-4637</phone>
      <phone_ext>228</phone_ext>
      <email>Heather.johansen@kadlec.org</email>
    </contact>
    <investigator>
      <last_name>Rangaswamy Chintapatla, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 5, 2018</study_first_submitted>
  <study_first_submitted_qc>February 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 9, 2018</study_first_posted>
  <last_update_submitted>May 22, 2018</last_update_submitted>
  <last_update_submitted_qc>May 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tumor Metabolism</keyword>
  <keyword>RCC</keyword>
  <keyword>Glutaminase Inhibitor</keyword>
  <keyword>CB-839</keyword>
  <keyword>CANTATA</keyword>
  <keyword>TKI</keyword>
  <keyword>Tyrosine Kinase Inhibitor</keyword>
  <keyword>cabozantinib</keyword>
  <keyword>Cabometyx</keyword>
  <keyword>Cometriq</keyword>
  <keyword>glutaminase</keyword>
  <keyword>glutamine</keyword>
  <keyword>renal cell</keyword>
  <keyword>clear cell</keyword>
  <keyword>kidney cancer</keyword>
  <keyword>cMET</keyword>
  <keyword>MET</keyword>
  <keyword>HGFR</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

